Brainstorm Cell Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BCLI Nasdaq 2830 www.brainstorm-cell.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Brainstorm Cell Therapeutics Inc.

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® - Jun 16th, 2025 6:30 am
BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial - May 28th, 2025 3:36 am
BCLI: Receives Regulatory Clearance to Initiate Phase 3b ALS Trial… - May 27th, 2025 7:10 am
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - May 27th, 2025 5:00 am
FDA grants clearance to BrainStorm’s Phase IIIb trial of ALS treatment - May 20th, 2025 5:24 am
Brainstorm Cell Therapeutics Inc (BCLI) Q1 2025 Earnings Call Highlights: Pivotal Phase 3b ... - May 20th, 2025 1:03 am
Sector Update: Health Care Stocks Advance Monday Afternoon - May 19th, 2025 11:50 am
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS - May 19th, 2025 5:00 am
BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - May 15th, 2025 2:05 pm
BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 - May 15th, 2025 5:30 am
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 - May 7th, 2025 4:30 am
BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit - May 6th, 2025 5:00 am
BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting - Apr 29th, 2025 4:30 am
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS - Apr 10th, 2025 5:30 am
Brainstorm Cell Therapeutics Inc (BCLI) Q4 2024 Earnings Call Highlights: Navigating Financial ... - Apr 1st, 2025 1:01 am
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - Mar 31st, 2025 5:00 am
BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq - Mar 26th, 2025 6:15 am
BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update - Mar 24th, 2025 5:00 am
BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS… - Jan 6th, 2025 3:05 am
BrainStorm Issues 2024 Letter to Shareholders - Dec 30th, 2024 6:00 am